Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01582750

Enrollment

Registered

2012-04-23

Start date

2010-10-31

Completion date

2015-12-31

Last updated

2013-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Keywords

endoscopic ultrasound, pre-operative concurrent chemoradiotherapy

Brief summary

The purpose of this study is to determine the role of endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values in predicting the tumor regression after concurrent chemoradiotherapy for rectal cancer.

Detailed description

We use endoscopic ultrasound to measure the primary tumor maximum diameter changes to predict the tumor regression after concurrent chemoradiotherapy for rectal cancer

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* pathologically confirmed rectal cancer, preoperative stage II / III (T3-4N0 or T1-4N + M0). * tumor distance from anus less than 12 cm. * KPS score not less than 70 * can be tolerated chemotherapy and radiotherapy. * pelvic who had no history of radiation therapy. * Non-allergic history of fluorouracil or platinum-based chemotherapy drugs. * a full understanding of the study, the ability to complete all of the treatment plan, follow up the conditions and sign the informed consent.

Exclusion criteria

* other malignancy (past or at the same time), does not include curable non-melanoma skin cancer and cervical carcinoma in situ; does not include resectable primary colon cancer (synchronous or metachronous). * pregnant or lactating patients. * fertility but did not use contraceptive measures. * existing active infection. * merge serious complications, can not tolerate the treatment, such as 6 months of myocardial infarction, mental illness, uncontrollable diabetes or uncontrollable hypertension or hypotension. * concurrent treatment with other anticancer drugs. * can not complete treatment or follow-up.

Design outcomes

Primary

Measure	Time frame
Endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values	3 months

Countries

China

Contacts

Primary ContactJing Jin, M.D.

jingjin1025@163.com861087788281

Backup ContactNing Li, M.D.

vista2400@gmail.com8610-87788280

Outcome results